Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
CONCLUSIONS: Elacestrant gained FDA approval in January 2023 and can be considered in patients with HR+ HER2- advanced breast cancer and ESR1 mutations who have progressed despite therapy with either CDK 4/6i plus aromatase inhibitors (AI) or fulvestrant or chemotherapy.PMID:37888769 | DOI:10.1177/10600280231206131
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Elizabeth Hageman Mia E Lussier Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Endocrine Therapy | HER2 | Hormones | Oral Cancer | Study